KenOliveLab Profile Banner
KenOliveLab Profile
KenOliveLab

@KenOliveLab

Followers
4K
Following
2K
Media
265
Statuses
3K

Asc Prof. of Medicine, Columbia University, views own. Pancreatic cancer, translational therapeutics, metabolism, systems, paracrine interactions. It all fits.

New York, NY, USA
Joined August 2018
Don't wanna be here? Send us removal request.
@KenOliveLab
KenOliveLab
2 years
OK, this one is really meaningful for our whole team. Our preclinical paper on pan-RAS inhibition in pancreatic cancer is now online @Nature. Led by OliveLab student @ulawasko and Revolution Medicines colleagues JingJing Jiang and Mallika Singh.
Tweet card summary image
nature.com
Nature - RMC-7977, a multi-selective RAS(ON) inhibitor, exhibits potent tumour-selective activity in multiple pre-clinical models of pancreatic ductal adenocarcinoma through a combination of...
19
58
218
@KenOliveLab
KenOliveLab
1 year
Sad to miss the first #PCAMChat24. Briefly, this is Ken Olive from @columbiacancer. I lead a translational research lab dedicated to #PDAC research. Excited to join in for part 2!
0
0
8
@KenOliveLab
KenOliveLab
1 year
Suddenly seeing a huge number of fellow scientists show up on BlueSky. FYI I'm one of them. Come follow me: @kenolivelab.bsky.social
2
0
3
@Aiims1742
Anirban Maitra
1 year
ICYMI, the new issue of @CR_AACR is online and features the print version of the In Focus commentary #PancreaticCancer–Associated Fibroblasts: Where Do We Go from Here? https://t.co/0FufRFesQI By Eileen Carpenter, @DebVendramini @MC_Hasselluhn @MaraShermanLab @Pasca_Lab
0
15
37
@KenOliveLab
KenOliveLab
1 year
New post on our website with updated information on the clinical development of RAS inhibitors for pancreatic cancer. I'll summarize on twitter sooner, but here's the full version:
1
14
41
@BHenickMD
Brian Henick
1 year
On behalf of our Phase I program @columbiacancer , proud of @bherzbergmd presenting exciting initial data on IDE397 in MTAP-del tumors at the @EORTC - @theNCI - @AACR conference https://t.co/Rnppvrh1aI We are excited to offer this study to our patients
ir.ideayabio.com
~33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSCLC patients 9 of 9 responses have confirmed by...
1
6
51
@KenOliveLab
KenOliveLab
1 year
Really excited for my postdoc @MC_Hasselluhn who received a 4th percentile score on her K99 application. Folks, she's on the job market!
10
1
67
@Aiims1742
Anirban Maitra
1 year
Revolution Medicines has launched its ph 3 study of RMC-6236 (RASolute 302) in patients with previously treated #PancreaticCancer. 1:1 randomization against physician’s choice of chemotherapy. A registration trial for KRAS inhibitor in pancreatic cancer! https://t.co/lyJx3lCI2M
4
55
149
@simonduerr
Simon Duerr
1 year
There is a new tool on BioIcons to turn any protein (in PDB format) into a 2D vector illustration in SVG format. You can upload any PDB file or import from PDB, AlphaFoldDB or ESMFoldDB. Feedback welcome :) https://t.co/grMysO8JV5
19
173
791
@columbiacancer
Herbert Irving Comprehensive Cancer Center
1 year
We are thrilled to welcome Michel Sadelain, MD, PhD, a global pioneer in CAR-T therapies, to Columbia and the HICCC.
@ColumbiaMed
Columbia Medicine
1 year
Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center. ➡️ https://t.co/g8OhtIBMxG
3
7
60
@ARNesLab
Luis Arnes
1 year
I am excited to see this story by my talented Master's Student, Kristina Høj. Her research dives into age-related decline in pancreas regeneration and how it’s linked to a proinflammatory response to injury. @AGA_GHAdvances,@UCPH_BRIC, https://t.co/43Jq2nefoI
2
2
15
@Aiims1742
Anirban Maitra
1 year
New online perspective article @CR_AACR article timed with the ongoing #PancreaticCancer stroma session at #AACRPan24 Pancreatic Cancer-Associated Fibroblasts: Where do we go from here? A conversation with three experts on the PDAC stroma (@MaraShermanLab @ednacukierman &
0
14
37
@KenOliveLab
KenOliveLab
1 year
Hiring committees take note...
@AlvaroCurielGa1
Alvaro Curiel-García, PhD
1 year
That feeling when you submit your first application for a tenure-track faculty! 🧑‍🔬 I am planing to create a "Translational systems oncology" laboratory focused on cell states, hypoxia and targeted therapies where I will use both wet and dry approaches. #faculty #academiclife
0
0
10
@cudldrc
CU-DLDRC
1 year
Congratulations to CU-DLDRC Associate Director, Timothy Wang, MD, who is the new Vice Chair for Academic Programs for the Department of Medicine at the Vagelos College of Physicians and Surgeons! Dr Wang will add this new role to his portfolio effective September 3rd, 2024.
0
1
15
@zeribechike
Zeribe Nwosu
1 year
@NwosuLab @CornellMBG has opened a call for postdoc applicants. Please kindly repost and or forward to potential applicants. Job posting: https://t.co/zw5qcPNEnW Lab website:
0
9
12
@KenOliveLab
KenOliveLab
1 year
When everything is urgent, nothing is urgent.
0
1
10
@KenOliveLab
KenOliveLab
1 year
The Olive Lab is looking for a postdoc to lead our translational program on RAS inhibition in pancreatic cancer. Should have exceptional scientific and project management skills, and experience with transdisciplinary research. Must be a good human.
2
38
84
@KenOliveLab
KenOliveLab
1 year
Really exciting times for the PDAC field, offering real hope for patients. This is just monotherapy. Can't wait to see combinations!
0
1
15
@KenOliveLab
KenOliveLab
1 year
Data available on their website at:
1
2
9
@KenOliveLab
KenOliveLab
1 year
They present a preliminary design of a planned Phase 3 trial in 2nd line PDAC patients, randomized to physician's choice.
2
2
11